Revenue from Contract with Customer, Excluding Assessed Tax of Ambrx Biopharma Cayman, Inc. from 31 Dec 2019 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Ambrx Biopharma Cayman, Inc. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Dec 2019 to 30 Jun 2023.
  • Ambrx Biopharma Cayman, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Jun 2023 was $1,123,000, a 14% decline year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $7,402,000, a 0.71% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $7,455,000, a 45% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $13,671,000, a 33% increase from 2019.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $1,123,000 -$176,000 -14% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $24,000 -$1,589,000 -99% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q2 2022 $1,299,000 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $1,613,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1

Ambrx Biopharma Cayman, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $7,402,000 -$53,000 -0.71% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023 2022 FY
2021 $7,455,000 -$6,216,000 -45% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $13,671,000 +$3,360,000 +33% 01 Jan 2020 31 Dec 2020 20-F 26 Apr 2022 2021 FY
2019 $10,311,000 01 Jan 2019 31 Dec 2019 20-F 26 Apr 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.